Compare medications

Max 4 meds. Sources include DailyMed labels; verify against official labeling. Last reviewed shown per row. On small screens the table defaults to a compact view—use “Show all columns” to view everything (scroll horizontally). Visit individual drug pages for narratives, printable summaries, and therapeutic drug monitoring notes.

Add up to 4 medications

0/4 selected

Browse catalog

Oral Antipsychotics

Second Generation Antipsychotics (SGAs)

First Generation Antipsychotics (FGAs)

Long‑acting Injectable Antipsychotics (LAIs)

Mood Stabilizers

Adjunctive Medications

Ketamine & rapid-acting antidepressants (2)

Benzodiazepines (12)

Sleep & circadian agents (14)

ADHD & wakefulness agents (14)

Substance use treatment & harm reduction (11)

Metabolic & weight management (4)

Other adjunctive medications (17)

Compact view hides Indications, MOA, PK, TDM, Monitoring, and Reviewed.

Medication	Indications (label)	Dosing highlights	MOA	PK	TDM	Risk flags	Monitoring	LAI options	Last reviewed
atomoxetineAdjunctive therapyBrands: STRATTERA View labelExact	Attention-deficit/hyperactivity disorder (ADHD). View labelExact	Adults often start at 40 mg/day, then increase to a target of 80 mg/day after several days to weeks; maximum recommended dose is 100 mg/day (label).	Selective norepinephrine reuptake inhibitor (non-stimulant ADHD medication).	CYP2D6 (major), CYP2C19 (minor) \| Single-dose range 5–24 h	No	—	Mood and suicidality monitoring in children/adolescents (boxed warning), especially early in treatment. Baseline and periodic blood pressure and heart rate (more often during titration). Appetite and weight tracking in children; consider growth monitoring when long-term. Fatigue/insomnia monitoring; dose timing or split dosing adjustments can help when limiting. Medication changes that affect CYP2D6 are worth reviewing when response or side effects change.	No	2026-02-12
methylphenidateAdjunctive therapyBrands: RITALIN, CONCERTA, DAYTRANA, METADATE CD, QUILLIVANT XR View labelExact	Attention-deficit/hyperactivity disorder (ADHD); narcolepsy (product-dependent). View labelExact	Adults (typical pattern): low morning dose with weekly titration based on benefit and tolerability; immediate-release products often need a noon dose, while extended-release products are typically once daily. Typical adult total daily dosing is often in the 10–60 mg/day range, but labeled maxima vary by product and delivery system; dose escalation that worsens sleep is typically avoided.	Central nervous system stimulant; inhibits dopamine and norepinephrine reuptake (DAT/NET).	CES1 (carboxylesterase) to ritalinic acid \| Single-dose mean 3 h	No	—	Baseline and periodic blood pressure and heart rate (more often during titration). Appetite and weight are tracked; meal and nutrition counseling is common if weight loss occurs. Sleep onset, total sleep time, and evening rebound are monitored; timing/formulation changes are often tried first. Anxiety, agitation, mood elevation, or hallucinations are monitored; stopping and reassessing is often considered if symptoms emerge. Misuse/diversion risk is reviewed, and safe storage counseling is commonly documented.	No	2025-12-29
lisdexamfetamineAdjunctive therapyBrands: VYVANSE View labelExact	Attention-deficit/hyperactivity disorder (ADHD); binge eating disorder in adults (product-dependent). View labelExact	Usually once daily in the morning; afternoon/evening dosing is typically avoided due to insomnia risk. Typical adult starting dose is 30 mg once daily, with titration in 10–20 mg steps (often weekly) based on response and tolerability.	Prodrug stimulant converted to dextroamphetamine; increases dopamine and norepinephrine signaling.	Enzymatic hydrolysis (blood) to dextroamphetamine \| Single-dose mean 11 h	No	—	Baseline and periodic blood pressure and heart rate (more often during titration). Appetite and weight/BMI are tracked; nutrition and meal timing are revisited if weight loss occurs. Sleep onset and duration are monitored; timing adjustments are often tried before adding sedatives. Anxiety, agitation, mood elevation, or hallucinations are monitored; if concerning symptoms emerge, discontinuation and reassessment are common. Misuse/diversion risk is reviewed and safe storage counseling is documented.	No	2025-12-29
guanfacine ERAdjunctive therapyBrands: INTUNIV View labelExact	Attention-deficit/hyperactivity disorder (ADHD) (extended-release formulation; product-dependent). View labelExact	Typically once daily. Morning dosing is common, but bedtime dosing can be considered when sedation is prominent. Dosing typically starts low and titrates weekly as tolerated. Typical doses are 1–4 mg/day (product- and age-dependent).	Alpha-2A adrenergic agonist (non-stimulant ADHD medication).	CYP3A4 \| Single-dose mean 17 h; Single-dose range 10–30 h	No	Sedation	Baseline and periodic blood pressure and heart rate, especially during titration. Sedation, dizziness, and orthostasis are commonly monitored; dose timing and titration speed are adjusted as needed. Interacting medications (CYP3A4 inhibitors/inducers) and other sedatives are typically reviewed. Taper planning in advance can reduce rebound hypertension and irritability.	No	2025-12-29

Compare tool FAQ

How many medications can I compare at once?

You can line up to four medications at a time. Use the search box to add or remove drugs, then press “Compare” to refresh the table.

Where does the comparison data come from?

Most fields are generated from our curated facts + per-drug profiles. DailyMed label links come from source metadata, and LAI options come from our LAI catalog.

Can I save or share a comparison?

Yes. The Share button copies a link you can send to teammates, and we store your most recent selection so you can restore it next time you visit.